Nugenerex Immuno-oncology, Inc. Increase (Decrease) in Accounts Payable
Nugenerex Immuno-oncology, Inc. reported Increase (Decrease) in Accounts Payable of $455.57 thousand for the 9-month period ending 2020-04-30, per its 10-Q filed 2020-06-19.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2020-06-19
- Nugenerex Immuno-oncology, Inc. increase (decrease) in accounts payable for the quarter ending 2020-04-30 was $88.67K, a 254.42% increase year-over-year.
- Nugenerex Immuno-oncology, Inc. increase (decrease) in accounts payable for the quarter ending 2019-04-30 was $25.02K.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month |
|---|---|---|---|
| 2020-04-30 | $88.67K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-06-19 | $455.57K 10-Q · filed 2020-06-19 | |
| 2020-01-31 | $366.90K 10-Q · filed 2020-06-17 | ||
| 2019-04-30 | $25.02K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-06-19 | $387.44K 10-Q · filed 2020-06-19 | |
| 2019-01-31 | $362.42K 10-Q · filed 2020-06-17 |